Skip to main content

Main navigation

Our Company
Research
- EPIDIOLEX® (cannabidiol) CV
- Pipeline
Patients
News
- Spotlight Articles
- Media Library
Careers
Contact
United States

NEWS

PRESS RELEASES

Exciting things are happening at Greenwich Biosciences. Here is the latest news about our company, products, and pipeline.

Greenwich Biosciences, Inc. is the US subsidiary of GW Pharmaceuticals plc. For general corporate information, please click here.

May 6, 2019

Greenwich Biosciences Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX^® (cannabidiol) Oral Solution CV in Patients with Seizures Associated With Tuberous Sclerosis Complex

May 2, 2019

Greenwich Biosciences to Present Data on FDA-approved EPIDIOLEX^® (cannabidiol) Oral Solution CV at the 2019 American Academy of Neurology Annual Meeting

Nov 27, 2018

Company Announces Results from Phase 3 Pivotal Trial for EPIDIOLEX^® (cannabidiol) Oral Solution CV in Patients with Dravet Syndrome

Nov 19, 2018

Greenwich Biosciences to Present New Data on FDA-approved EPIDIOLEX^® (cannabidiol) Oral Solution CV at the American Epilepsy Society Annual Meeting

Nov 1, 2018

EPIDIOLEX^® (cannabidiol) Oral Solution CV – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.

Jun 25, 2018

Greenwich Biosciences Announces FDA Approval of EPIDIOLEX^® (cannabidiol) Oral Solution CV - the First Plant-derived Cannabinoid Prescription Medicine

INVESTORS

For investor inquiries and media, please contact:

Stephen Schultz
Vice President, Investor Relations
917.280.2424 Tel.
760.795.2219 Fax
Email

Christy Curran
Sam Brown Inc.
615-414-8668 Tel.
Email

Spotlight Articles

Exciting things are happening at Greenwich Biosciences. View the latest news about our company, products, and pipeline.

Media Library

Explore helpful downloads and information.

LinkedIn
Twitter

Follow Us

Keep up with the latest news and updates about Greenwich Biosciences through social media.

Footer

Home
Our Company
Research
Patients
News
Careers
Contact
LinkedIn
Twitter

This website is sponsored by Greenwich Biosciences, Inc.

This site is not intended to provide medical advice or to suggest that any product mentioned is safe or efficacious for any disease or condition

second footer

Site Map
Privacy Policy
Terms of Use
Unsubscribe

©2020 Greenwich Biosciences, Inc. All rights reserved.
GBS-02157-0220

You are leaving the website of Greenwich Biosciences, Inc., the US subsidiary of GW Pharmaceuticals plc. This link will take you to a website to which our Privacy Policy does not apply.

Proceed to Website >

Stay on greenwichbiosciences.com >

Medical Inquiry Form

For questions about scientific and clinical information regarding Greenwich Biosciences products, complete the form below.

If you would like to contact Medical Information by phone, call (833) 424-6724

Request Type

Request Medical Information

Request to be contacted by a Medical Science Liason

Request a live cannabinoid presentation

TITLE

FIRST NAME (REQUIRED)

LAST NAME (REQUIRED)

EMAIL (REQUIRED)

SPECIALTY

PREFERRED CONTACT METHOD

Email

Phone

Mail

PHONE (REQUIRED)

Address Fields

STREET ADDRESS LINE 1 (REQUIRED)

STREET ADDRESS LINE 2

CITY (REQUIRED)

STATE (REQUIRED)

ZIP (REQUIRED)

MEDICAL INQUIRY

By clicking Send Request, I confirm that this is an unsolicited request and consent to receive communications from Greenwich Biosciences, Inc.

Leave this field blank

Status message

Sorry...This form is closed to new submissions.

COVID-19 UPDATE

We are closely monitoring our supply chain of EPIDIOLEX^® (cannabidiol) CV and, at this time, do not foresee any supply interruptions in the United States.

At Greenwich Biosciences, our main concern is the well-being of our patients, healthcare partners, and employees. Our hearts and thoughts go out to the people who have been affected. We are monitoring the COVID-19 situation and have taken steps to ensure that access and assistance for patients remain consistent.